News Headlines

  1. UCB And Antengene Enter Global License Agreement For ATG-201, A B Cell-Depleting Bispecific Antibody 3/3/2026

    UCB, a global biopharmaceutical company, and Antengene Corporation Limited (Antengene), an innovative, commercial-stage global biotech company today announced that they have entered into an agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201 and access to its associated manufacturing technology in relation to ATG-201.

  2. Aspire Biopharma Partners With Microsize To Develop Rapid-Delivery Sublingual Powder Formulation Of Alprazolam For Faster Anxiety Relief 3/3/2026

    Aspire Biopharma Holdings, Inc. ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted, patent-pending drug delivery technology, today announced a strategic partnership with Microsize (Quakertown, Pennsylvania), the largest independent North American contract development and manufacturing organization (CDMO) focused on cGMP micronization and particle size engineering.

  3. The Progeria Research Foundation And Forge Biologics Announce Manufacturing Partnership To Advance Gene Therapy For Children With Progeria 3/3/2026

    The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a manufacturing agreement to support the development and manufacturing of SamPro-2, PRF’s investigational gene therapy for children and young adults living with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging.

  4. FUJIFILM Biotechnologies Unveils ShunzymeX Precision Purification Technology 3/3/2026

    FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today unveils ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics.

  5. Cure Rare Disease And LGMD2L Foundation Announce Multi-Year Partnership To Develop Gene Therapy For Anoctamin 5-Related Disease 3/2/2026

    Cure Rare Disease (CRD), a non-profit biotechnology organization, today announced a landmark partnership with the LGMD2L Foundation.

  6. Congruence And Ono Pharma Expand Multi-Target Research Partnership With The Addition Of Two New Programs 3/2/2026

    Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Congruence Therapeutics today announced that they have expanded their existing multi-target research partnership through the execution of a new research collaboration for two additional programs.

  7. WuXi XDC Enters Strategic Collaboration With Earendil Labs On WuXiTecan-2 Payload-Linker Technology Platform 2/27/2026

    WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform.

  8. Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas 2/26/2026

    Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. 

  9. Eckert & Ziegler Enters Partnership With Molecular Partners To Support Development Of Radio-DARPin Therapeutics 2/26/2026
  10. Quotient Sciences Extends Commercial Manufacturing Partnership For Ultra-Rare Disease Treatment 2/26/2026

    Quotient Sciences, a leading integrated CRDMO, announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.